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Aims Here we investigated the mechanisms by which cardiovascular CB1 cannabinoid receptors may modulate the cardiac
dysfunction, oxidative stress, and interrelated cell death pathways associated with acute/chronic cardiomyopathy
induced by the widely used anti-tumour compound doxorubicin (DOX).
Methods
and results
Both load-dependent and -independent indices of left-ventricular function were measured by the Millar pressure–
volume conductance system. Mitogen-activated protein kinase (MAPK) activation, cell-death markers, and oxi-
dative/nitrosative stress were measured by molecular biology/biochemical methods and flow cytometry. DOX
induced left-ventricular dysfunction, oxidative/nitrosative stress coupled with impaired antioxidant defense, activation
of MAPK (p38 and JNK), and cell death and/or fibrosis in hearts of wide-type mice (CB1
þ/þ), and these effects were
markedly attenuated in CB1 knockouts (CB1
2/2). In human primary cardiomyocytes expressing CB1 receptors
(demonstrated by RT–PCR, western immunoblot, and flow cytometry) DOX, likewise the CB1 receptor agonist
HU210 and the endocannabinoid anandamide (AEA), induced MAPK activation and cell death. The DOX-induced
MAPK activation and cell death were significantly enhanced when DOX was co-administered with CB1 agonists
AEA or HU210. Remarkably, cell death and MAPK activation induced by AEA, HU210, and DOX+AEA/HU210
were largely attenuated by either CB1 antagonists (rimonabant and AM281) or by inhibitors of p38 and JNK
MAPKs. Furthermore, AEA or HU210 in primary human cardiomyocytes triggered increased reactive oxygen
species generation.
Conclusion CB1 activation in cardiomyocytes may amplify the reactive oxygen/nitrogen species-MAPK activation-cell death
pathway in pathological conditions when the endocannabinoid synthetic or metabolic pathways are dysregulated
by excessive inflammation and/or oxidative/nitrosative stress, which may contribute to the pathophysiology of
various cardiovascular diseases.
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1. Introduction
Numerous preclinical and clinical studies have reported increased
endocannabinoid levels and implicated cannabinoid-1 (CB1) recep-
tor activation by endocannabinoids in the pathogenesis of hypoten-
sion and/or cardiac dysfunction associated with various forms of
shock and cardiomyopathies, as well as in the development of
obesity, increased cardiometabolic risk, atherosclerosis, and
impaired glucose tolerance.1– 5 Multiple studies found beneficial
effects of CB1 antagonists in these pathological conditions, both
in animal models as well as in human trials. CB1 activation may
also lead to undesirable haemodynamic consequences in healthy
volunteers depending on the duration of the use (bradycardia/
tachycardia, hypotension, arrhythmias),6 which can be attenuated
by CB1 blockade.
7,8 Furthermore several clinical cases of myocar-
dial damage/cardiomyopathy associated with cannabis use have
also been reported9 (see also references within).
The quinone-containing anthracycline doxorubicin (DOX) is a
potent anti-tumour compound commonly used to treat several
malignancies. The major limitation of this class of drug is its dose-
dependent cardiotoxicity, resulting in the death of cardiomyocytes
which often leads to irreversible myocardial dysfunction.10 The
pathogenesis of DOX-induced cardiomyopathy/heart failure is
complex and may involve multiple mechanisms including increased
oxidative/nitrosative stress,11,12 mitochondrial dysfunction/
damage,12 alterations in the excitation–contraction (EC) coup-
ling,13 and activation of mitogen-activated protein(MAP)kinases,14
just to name a few.
We have recently demonstrated that DOX increased endocan-
nabinoid levels in cardiomyocytes both in vivo and in vitro, and that
the pharmacological inhibition of CB1 attenuated the DOX-
induced myocardial dysfunction in a clinically relevant mouse
model of acute cardiomyopathy.15 However, the role of the cardi-
ovascular CB1 cannabinoid receptors and its possible interplay
with the oxidative/nitrosative stress and interrelated cell death sig-
nalling pathways, eventually culminating into cardiac dysfunction,
have not been addressed; likewise the fundamentals of CB1-
mediated signalling in human cardiomyocytes, and its possible
role in cell death and reactive oxygen species generation are also
elusive. Therefore, using human primary cardiomyocytes and CB1
knockout mice we aimed to investigate the CB1-mediated signalling
in cardiomyocytes and its possible role in oxidative stress, inter-
related signalling and cell death pathways associated with clinically
relevant acute and chronic cardiomyopathy models induced by
DOX. In the chronic cardiomyopathy model, we also investigated
the possible involvement of CB1 receptors in myocardial fibrosis.
2. Methods
2.1 Animals
Protocols involving the use of animals were approved by the Insti-
tutional Animal Care and Use Committees and were performed in
line with the National Institutes of Health (NIH) guidelines for the
care and use of laboratory animals (NIH Publication No. 85-23,
revised 1996). Male CB1
þ/þ or CB1
2/2 mice (25–30 g), maintained at
NIAAA’s breeding facility, were administered with single dose
(20 mg/kg) of DOX-HCl (Sigma Chemicals, St Louis, MO)
intraperitoneally (i.p.) or with multiple doses (5 mg/kg) at days 1, 7,
14, and 21. After 5 or 35 days, mice were subjected to haemodynamic
measurements or hearts were excised and snap frozen in liquid
nitrogen for biochemical measurements as described.15,16
2.2 Reagents and cell culture
DOX was purchased from Sigma chemicals (MO, USA); p38 myocardial
mitogen-activated protein kinase (MAPK), JNK inhibitors (SB203580 and
JNK inhibitor II, respectively) was obtained from Calbiochem, EMD
(Gibbstown, NJ). Anandamine (AEA), (6aR,10aR)-9-(hydroxymethyl)-
6,6dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]
chromen-1-ol (HU210), and 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-
4-methyl-N-4-moepholinyl-1H-pyrazole-3-carboxamide (AM 281)
were purchased from Tocris Bioscience (Ellisville, MO). N-Piperidino-
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-carbox-
amide (SR 141716A-Rimonabant;indicated as SR1) was obtained from
NIDA Drug Supply Program (Research Triangle Park, NC) as
described.15 b-Actin antibody was purchased from Chemicon (Teme-
cula, CA), cleaved caspase-3, phospho(Thr180/Tyr182)-p38MAPK/
p38MAPK, phospho(Thr183/Tyr185)-JNK/JNK, and cytochrome c
(Cyt-c), cytochrome c oxidase (COX-IV) rabbit polyclonal antibodies
were from Cell Signaling Technology (Danvers, MA). CB1 rabbit C-
terminal polyclonal antibody for the Western was developed as
described.17 CB2 rabbit polyclonal antibody for the Western was from
Cayman Chemicals (Ann Arbor, MI). Flow cytometry reagents-Sytox
Green and AnnexinV-APC were obtained from Molecular Probes (Invi-
trogen, Carlsbad, CA). Human cardiac myocytes (HCM) were obtained
from ScienCell Research Laboratories (Carlsbad, CA) and cultured in
poly-lysine coated plates using complete cardiac myocyte medium
according to the manufacturer’s recommendation as described.18
2.3 Haemodynamic measurements in mice
Left-ventricular performance was analysed in mice anesthetized with
2% isoflurane using Millar pressure–volume conductance system
(Millar Instruments, TX) as described.15,16,19
2.4 Western blot analysis
Protein extraction from myocardial tissue homogenates or cardiomyo-
cytes, loading, incubations with antibodies, development, and analysis
were as described.12
2.5 Real-time PCR and semi-quantitative
RT–PCR
Total RNA was isolated from heart homogenate or cardiac myocytes
using Trizol reagents (Invitrogen, Carlsbad, CA) according to manufac-
turer’s instruction. Analysis of mRNA expressions was performed as
previously described15,20 and all primers are indicated in the sup-
plements (see Supplementary material online).
2.6 Determination of myocardial superoxide
dismutase, glutathione peroxidase, PARP and
caspase 3/7 activities, nitrotyrosine and GSH
content, and DNA fragmentation
Myocardial PARP, caspase 3/7, superoxide dismutase (SOD), gluta-
thione peroxidase (GPx) activities, nitrotyrosine and GSH content,
DNA fragmentation were determined as previously described.12,15,21
2.7 TUNEL staining
Paraffin sections were dewaxed and in situ detection of apoptosis in
the myocardial tissues was performed by terminal
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deoxynucleotodyltransferase mediated nick-end labelling (TUNEL)
assay as per the instruction provided with the kit (Roche Diagnostics,
Indianapolis). After TUNEL labelling, sections were stained with mono-
clonal a-actinin antibody (cardiomyocyte marker, 1:100 dilution, DBS,
CA) for 1 h, followed by incubation with appropriate secondary anti-
body conjugated with Texas Red. Nucleus was labelled with Hoechst
33258 (Molecular probes, Invitrogen, CA) and the TUNEL positive
labelled cardiomyocyte/endothelial cells were observed using confocal
imaging microscope (Carl Zeiss, NY) using 40 objective at 2048 
2048 resolution.
2.8 Myocardial 4-hydroxynonenal content
4-Hydroxynonenal (4-HNE) in the myocardial tissues was determined
using the kit (Cell Biolabs, San Diego). In brief, BSA or myocardial
tissue extracts (10 mg/mL) are adsorbed on to a 96-well plate for
12 h at 48C. 4-HNE adducts present in the sample or standard are
probed with anti-HNE antibody, followed by an HRP-conjugated sec-
ondary antibody. The HNE-protein adducts content in an unknown
sample is determined by comparing with a standard curve.
2.9 Fatty acid amide hydrolase activity
Fatty acid amide hydrolase (FAAH) activities in the myocardial tissues
were determined using the kit from Cayman (Ann Harbor, MI). FAAH
hydrolyses AMC arachidonoyl amide resulting in the release of the flu-
orescent product, 7-amino-4-methylcoumarin (AMC). The flurophore
was analysed using an excitation wavelength of 340–360 nm and an
emission wavelength of 450–465 nm.
2.10 CB1/2 receptor expression in HCM
CB1/2 receptor expression in HCM was determined by flow cytometry
using rabbit anti-human CB1 N-terminal and CB2 rabbit polyclonal anti-
body from Cayman Chemicals (Ann Arbor, MI). In addition, a-actinin
(DBS, Pleasanton, CA) expression was also determined by intracellular
staining followed by flow cytometry to confirm the phenotype of
human cardiomyocytes.
2.11 Determination of apoptosis and ROS
generation by flow cytometry
After the treatments, apoptosis/necrosis of HCM was determined
using flow cytometry as described.15,22,23
2.12 Statistical analysis
Results are expressed as mean+ SEM. Statistical significance among
groups was determined by one-way ANOVA followed by Newman–
Keuls post hoc analysis using GraphPad Prism 5 software (San Diego,
CA). Probability values of P, 0.05 were considered significant.
3. Results
3.1 Genetic deletion of CB1 attenuates
acute DOX-induced cardiac dysfunction
Treatment of CB1
þ/þ mice with acute DOX, 20 mg/kg i.p. (DOX;
Figure 1) induced marked decrease in LVSP, þdP/dt, stroke work,
ejection fraction, cardiac output, and load-independent indexes
of contractility (PRSW, dP/dt-EDV, and Emax, respectively)
5 days following the drug administration, and an increase in
LVEDP and prolongation of relaxation time constants (t Weiss
and Glantz). These changes were significantly attenuated in CB1
knockouts (Figure 1).
3.2 Genetic deletion of CB1 attenuates
acute DOX-induced myocardial
oxidative/nitrosative stress, impaired
antioxidant defense, and inactivation
of endocannabinoid metabolizing
enzyme FAAH
As shown in Figure 2, acute DOX administration increased markers
of oxidative/nitrosative stress [4-hydroxy-trans-2-nonenal (HNE)
and nitrotyrosine; Figure 2A] by 5.3 and 7.8-fold in the myocar-
dium of CB1
þ/þ mice, decreased myocardial total glutathione
content, SOD, and GPx activities (markers of antioxidant
defense) by 48, 30, and 36%, respectively (Figure 2B), and attenu-
ated the activity of the endocannabinoid AEA metabolizing enzyme
FAAH by 42% (Figure 2C). These changes were significantly less
pronounced in CB1
2/2 mice (Figure 2C).
3.3 The DOX-induced MAPKs activation,
Cyt-c release, caspase 3/7, and PARP
activity and cell death are attenuated
in the myocardium of CB1
2/2 mice
As shown in Figure 3, DOX-induced activation of p-38 and JNK
MAPKs (Figure 3A), and Cyt-c release (Figure 3B) in the myocar-
dium of CB1
þ/þ mice 5 days following administration. These
changes were significantly attenuated in CB1
2/2 mice (Figure 3).
DOX also markedly increased myocardial apoptotic and PARP-
dependent cell death (caspase 3 cleavage, caspase3/7, and PARP
activity by 8.7, 4.2, and 6.4-fold, respectively) in CB1þ/þ mice.
These changes were significantly attenuated in CB1
2/2 mice
(Figure 4A–C ). CB1
2/2 mice treated with DOX had decreased
number of TUNEL positive cardiomyocytes and endothelial cells
(Figure 4D).
3.4 Genetic deletion of CB1 attenuates
chronic DOX-induced cardiac
dysfunction, fibrosis, oxidative stress,
and cell death
Treatment of CB1
þ/þ mice with multiple doses of DOX (5 mg/kg)
at days 1, 7, 14, and 21 (Figure 5D), induced a significant decrease in
LVSP, þdP/dt, stroke work, ejection fraction, cardiac output, and
load-independent indexes of contractility (PRSW, dP/dt-EDV, and
Emax, respectively) 35 days following the drug administration,
and an increase in LVEDP and prolongation of relaxation time con-
stants (t Weiss and Glantz). These changes were significantly atte-
nuated in CB1 knockouts (Figure 5A). Chronic (but not acute)
DOX administration (Figure 5B; see Supplementary material
online, Figure S1) was associated with increased myocardial fibrosis
in CB1
þ/þ mice, which was almost completely absent in knockouts.
Chronic DOX (cDOX) administration was also associated with
marked increases in myocardial HNE and nitrotyrosine formation
(8.4 and 5.5-fold; Figure 6A), caspase 3/7 activity, and DNA frag-
mentation (5.4 and 5.1-fold; Figure 6B), mRNA expression of
NADPH oxidase isoforms gp91phox, NOX4, and p67phox
(2.6, 2.5, 2.1-fold) and matrix metalloproteinases 2 and 9 (2.7
CB1 mediates cell death in cardiomyocytes 775
Figure 1 Improved DOX-induced acute cardiac dysfunction in CB1 knockout mice. (A) Representative baseline pressure–volume (P–V)
loops and derived parameters. Panels at right show volume (red), pressure (blue), and +dP/dt (green) derived from the pressure signal. DOX-
induced profound cardiac dysfunction in CB1
þ/þ mice evidenced by rightward shift of P–V relations, decrease in left-ventricular systolic pressure
(LVSP), maximum first derivative of ventricular pressure with respect to time (þdP/dt), stroke work, ejection fraction, cardiac output, and an
increase in left-ventricular end-diastolic pressure (LVEDP), and prolongation of relaxation time constants (t Weiss and Glantz) 5 days following
the administration of 20 mg/kg intra-peritoneally. These changes were largely attenuated in CB1
2/2 mice. (B) Representative pressure–volume
(P–V) loops at different preloads after vena cava occlusion, showing differences in the end-systolic P–V relation (ESPVR) in CB1
þ/þ and CB1
2/2
mice treated with vehicle or DOX. The less steep ESPVR in DOX-treated mice indicates decreased contractile function, which was less pro-
nounced in CB1
2/2 mice treated with DOX compared with CB1
þ/þ mice treated with the drug. DOX markedly decreased load-independent
indexes of contractility [preload-recruitable stroke work (PRSW), dP/dt–end-diastolic volume relation (dP/dt–EDV), and end-systolic
pressure–volume relation (Emax), respectively] in CB1
þ/þ mice, which was attenuated in knockouts. Results are mean+ SEM of 8–11 exper-
iments/group. *P, 0.05 vs. vehicle; #P, 0.05 CB1
þ/þ þ DOX.
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and 2.1-fold, respectively) in CB1
þ/þ mice. These changes were sig-
nificantly attenuated in knockouts (Figure 6C and D).
3.5 CB1 and CB2 receptors expressed in
cultured human primary cardiomyocytes
CB1 and to a less extent CB2 receptors were expressed in human
cardiomyocytes as determined by RT–PCR, real-time PCR,
western blot, and flow cytometry (see Supplementary material
online, Figure S2). CB1/2 expressions were not affected by the treat-
ment with 500 nM DOX (see Supplementary material online,
Figure S2).
3.6 CB1 agonist HU210 and the
endocannabinoid AEA induce
MAPK activation
Figure 7A and B show dose- and time-dependent activation of
MAPKs by HU210 and AEA in HCM, respectively. Combination
of DOX with CB1 agonists markedly enhanced the activation of
MAPKs (Figure 7C). These effects were attenuated by CB1 antagon-
ist (Figure 7C). Collectively, these observations suggest that CB1
receptor activation is coupled with activation of MAPKs in HCM.
3.7 CB1 receptor antagonists attenuate
the DOX/HU210/AEA- or their
combination-induced cell death in HCM
As shown in Figure 8A and B; see Supplementary material online,
Figures 3 and 4, DOX, HU210, or AEA treatment(16 h) induced
cell death in HCM, which were attenuated by the CB1 antagonists
Figure 2 Acute DOX-induced myocardial oxidative/nitrosative
stress, impaired antioxidant defense is attenuated in CB1
2/2 mice.
(A) Showsthe lipid peroxides (4hydroxynonenal—4HNE)and nitro-
tyrosine (NT) accumulation in the groups as indicated. (B) Depicts
myocardial glutathione peroxidase, superoxide dismutase (SOD)
activities, and glutathione content. (C) Myocardial endocannabinoid
metabolizing enzyme (FAAH) activity as indicated. *P, 0.05 vs.
vehicle; #P, 0.05 vs. CB1
þ/þ þ DOX (n ¼ 6–10/group).
Figure 3 Acute DOX-induced myocardial MAPKs activation and cytochrome c release is attenuated in CB1
2/2 mice. (A) Representative blots
depicting the MAPK activation in CB1
þ/þ or CB1
2/2 mice treated with DOX. (B) Representative western immunoblot depicting the cytochrome
c release in the cytosol, 5 days after DOX administration. *P, 0.05 vs. vehicle; #P, 0.05 vs. CB1
þ/þ þ DOX (n ¼ 6/group).
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Figure 4 Acute DOX-induced myocardial apoptosis/necrosis is attenuated in CB1
2/2 mice. (A) Cleaved caspase 3 activation by western blot
analysis and (B) caspase 3/7 and (C) PARP activity in myocardial tissues from CB1
þ/þ or CB1
2/2 mice treated with vehicle or DOX 5 days follow-
ing the exposure. *P, 0.05 vs. vehicle; #P, 0.05 vs. CB1
þ/þ þ DOX (n ¼ 6/group). (D) Representative TUNEL staining (green), showing that
the DOX-induced apoptosis was present both in cardiomyocytes and endothelial cells, which was attenuated in CB1
2/2 mice, irrespective of the
cell type. Red colour represents cardiomyocyte specific a-actinin staining, blue nuclei of all cells, green or light green/white TUNEL positive cells
(the latter in overlaid images). There were no TUNEL positive cells in vehicle treated mice (data not shown).
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Figure 5 Improved DOX-induced chronic cardiac dysfunction and decreased myocardial fibrosis in CB1 knockout mice. (A) Treatment of
wide type CB1
þ/þ mice with (cDOX), 5 mg/kg intra-peritoneally at days 1, 7, 14, and 21 induced a significantly decreased left-ventricular systolic
pressure, maximum first derivative of ventricular pressure with respect to time (þdP/dt), stroke work, ejection fraction, cardiac output, and
load-independent indexes of contractility (PRSW, dP/dt–EDV, Emax), and an increase in left-ventricular end-diastolic pressure (LVEDP) and
prolongation of relaxation time constants (t Weiss and Glantz) 35 days following its administration, which was attenuated in CB1
2/2 mice.
(B) Genetic deletion of CB1 attenuates chronic DOX(cDOX)-induced myocardial fibrosis Left: Sirius red staining of paraffin sections of
heart tissues from respective groups and treatments as shown. Right: quantitative real-time PCR for the mRNA expression of fibrosis
markers in the myocardium as indicated. Results are mean+ SEM of 10–14 experiments in each group for haemodynamics measurements,
and 6/group for gene expressions. *P, 0.05 vs. vehicle in CB1
þ/þ/CB1
2/2 mice; #P, 0.05 vs. CB1
þ/þ þ DOX.
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SR1/AM281, respectively. Combination of DOX with CB1 ago-
nists markedly enhanced the cell death (Figure 8B; see Sup-
plementary material online, Figure S4). Cell death induced by
DOX/HU210/AEA- or their combination could also be attenu-
ated by CB1 inhibitors in HCM (Figure 8B; see Supplementary
material online, Figure S4), likewise with inhibitors of p38 and
JNK MAPKs (see Supplementary material online, Figure S5).
3.8 CB1 activation increases ROS
generation in HCM
AEA, HU210 induced ROS generation in HCM (measured 2 h after
the treatment), which was attenuated by CB1 antagonists SR1 and
AM 281, respectively (Figure 8C).
4. Discussion
The primary cannabinoid receptors in the CNS are CB1 receptors
that predominantly couple to inhibitory G proteins (Gi and Go)
and under certain conditions also to Gs or Gq/11 leading to the inhi-
bition of adenylyl cyclase and certain calcium channels together
with the activation of inwardly rectifying potassium channels and
several different MAP kinases.24 Indeed, there is increasing recent
recognition that CB1 signalling involves activation of MAP kinases
in a variety of cell types;24 however, the existence and possible
role of this pathway in cardiomyocytes is unknown. CB1 receptors
are also present, along with their natural ligands, the endocannabi-
noids (AEA and 2-AG), and metabolizing enzymes in rodent15,25
and human myocardium26 or cardyomyocytes (see Supplementary
material online, Figure S2), and these receptors may mediate
various cardiovascular depressive effects and contribute to the car-
diovascular pathological alterations associated with multiple cardi-
ovascular disorders via largely unexplored mechanisms.5,6 Indeed,
numerous experimental studies have demonstrated that activation
of the endocannabinoid system contributes to hypotension and
compromised cardiovascular function in a variety of pathophysio-
logical states (e.g. endotoxic, haemorrhagic, and cardiogenic
shock, advanced liver cirrhosis, and cirrhotic cardiomyopathy)
through the activation of cardiovascular CB1 receptors,
6
however the underlying signalling mechanism were not explored.
Sustained activation of CB1 receptors by endocannabinoids
appears to increase cardiovascular risk factors in obesity/metabolic
syndrome and diabetes.3,5 These risk factors include plasma lipid
alterations, abdominal obesity, hepatic steatosis, and insulin and
leptin resistance.1 –3 Previously we have provided evidence that
endocannabinoid AEA levels were elevated in the hearts from
the well-established mouse model of acute DOX-induced cardio-
myopathy and in vitro in rat-derived cardiomyocytes exposed to the
drug, and that CB1 antagonists improved compromised contractile
function and protected against DOX-induced apoptosis, however
the role of the underlying signalling mechanisms and the specificity
of these effects were not addressed.
In this study, using CB1 knockout mice and human primary car-
diomyocytes, we provide evidence on the important role of CB1-
mediated signalling in cardiomyocytes in oxidative stress, inter-
related signalling and cell death associated with a clinically relevant
acute and chronic model of cardiomyopathy induced by DOX. We
demonstrate that the activation of CB1 receptors in human
Figure 6 cDOX-induced myocardial oxidative/nitrosative stress and cell death is attenuated in CB1
2/2 mice. Myocardial (A) HNE and nitro-
tyrosine accumulation, (B) apoptosis markers and mRNA expressions of (C ) NADPH oxidase isoforms (gp91phox, NOX4, p67, and p47phox)
and (D) metalloproteinases 2 and 9 (MMP2/9). *P, 0.05 vs. vehicle; #P, 0.05 vs. CB1
þ/þ þ DOX (n ¼ 6–10/group).
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Figure 7 CB1 receptor activation with synthetic/endogenous agonists or DOX induces CB1-dependent MAPK activation in human cardio-
myocytes (HCM). Concentration- and time-dependent effects of HU210 (A) and AEA (B) on activation of p38 and JNK MAPKs. (C) DOX-,
AEA-, HU210, or DOX+AEA/HU210-induced MAPKs activation is attenuated by CB1 receptor antagonist SR141716(SR1). HCM were
treated with HU210, AEA, DOX, or SR1 alone at indicated concentrations for 40 min or first treated with SR1 for 1 h, followed by continued
incubation with DOX alone or in combination with AEA/HU210 for 40 min, and MAPK activation was determined by western blot. Shows
MAPK activation upon respective treatments. Adjacent panels describe the quantification (represented as fold change). *P, 0.05 vs.
vehicle; #P, 0.05 vs. cells treated without SR1 with indicated treatments (n ¼ 4).
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cardiomyocytes by the endocannabinoid AEA or the CB1 agonist
HU210 or DOX results in increased ROS generation, activation
of various MAP kinases (p38 and JNK), and consequent cell
death, which are attenuated by both selective CB1 antagonists
and MAPK inhibitors. Furthermore, DOX-induced MAPK acti-
vation and cell death in human cardiomyocytes were significantly
enhanced when DOX was co-administered with AEA or HU210,
an effect which could also be attenuated by both CB1 antagonists
and MAPK inhibitors. There is increasing recognition that MAPK
activation contributes to DOX-induced cell death and cardiotoxi-
city,14 which is consistent with our observation in human cardio-
myocytes, as well as marked activation of p38 and JNK in the
myocardium of wide type mice (CB1
þ/þ) in our DOX-induced
acute cardiomyopathy model. Marked MAPKs activation has also
been reported in humans with advanced heart failure/dilated cardi-
omyopathy.27 Notably, reactive oxygen and nitrogen species (e.g.
superoxide, peroxynitrite, and hydrogen peroxide) importantly
implicated in the development of DOX-induced cardiomyopathy,
as well as in the development of numerous other cardiovascular
pathologies by multiple mechanisms,28– 32 also dose-dependently
activate MAPKs in cardiomyocytes leading to cell demise.33 In
addition to promoting cell death, these reactive oxidants may
also affect Ca2þ transients and/or b-adrenergic response in cardi-
omyocytes leading to impaired contractility.31,34,35 Indeed, the
DOX-induced alterations in EC coupling in cardiomyocytes can
be prevented by antioxidant N-acetylcystein, supporting this
notion.13 There is also increasing recognition that oxidative/nitro-
sative stress leads to increased expression and activation of matrix
metalloproteinases (MMPs) and other signalling pathways promot-
ing myocardial remodelling/fibrosis.36,37
In the acute DOX-induced cardiomyopathy model the severe
cardiac dysfunction starts to develop 3 days after the DOX admin-
istration and peaks at day 5 parallel with the marked increases in
myocardial nitrotyrosine generation and cell death followed by
severe mortality in mice shortly thereafter.15,16,38,39 In this
model, time-dependent increases of myocardial MMP2/9 gene
expression/activity were also reported12,40,41 coinciding with the
increased myocardial nitrotyrosine generation in mice,12 underlying
the importance of peroxynitrite/nitrosative stress in triggering the
activation of MMPs.36 At a time of the functional and biochemical
measurements we could not detect myocardial fibrosis in the acute
DOX-induced cardiomyopathy model (see Supplementary
material online, Figure S1). Consistently with previous reports,
acute administration of DOX increased myocardial oxidative/nitro-
sative stress and MAPK activation, impaired antioxidant defense,
and lead to left-ventricular dysfunction and increased apoptotic
and PARP-mediated cell death.12,15,16,38,39 Remarkably, the DOX-
induced myocardial MAPK activation, oxidative/nitrosative stress,
mitochondrial dysfunction, cell death, and cardiac dysfunction
were significantly attenuated in CB1
2/2 mice, suggesting an
Figure 8 HU210/AEA/DOX or their combination-induced cell death is attenuated by CB1 antagonists in human cardiomyocytes (HCM); CB1
activation increases ROS generation in HCM. (A and B) Cells were treated as indicated and cell death was determined by flow cytometry as
described in the methods (A) *P, 0.05 vs. vehicle; #P, 0.05 vs. HU210 (n ¼ 4) (B) *P, 0.05 vs. vehicle; †P, 0.05 vs. AEA/HU210 alone;
#P, 0.05 vs. AEA+HU210+DOX treated cells (n ¼ 4). (C) Shows the quantification of ROS generation by flow cytometry as per the treat-
ments indicated. *P, 0.05 vs. vehicle; #P, 0.05 vs. AEA/HU210 (n ¼ 4). (see also Supplementary material online, Figure S4).
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important role of these receptors in the development of the
above-mentioned pathophysiological processes.
Because previous studies reported marked antifibrotic effects of
CB1 receptor deletion or pharmacological inhibition in various
experimental models of liver fibrosis,42 we hypothesized that CB1
deletion may also influence the fibrosis in the myocardium. To inves-
tigate this we also utilized a chronic model of DOX-induced cardi-
omyopathy induced by multiple low doses of the drug.16,39 In this
model, genetic deletion of CB1 was associated with almost complete
absence of DOX-induced myocardial fibrosis (in addition to
decreased oxidative nitrosative/stress, MMP2/9 gene expression,
and cell death). Although we have recently identified mitochondria
as the primary source of myocardial DOX-induced ROS generation
both in vitro and in vivo in the acute cardiomyopathy model,12 we did
not exclude additional contribution of NADPH oxidases to this
process in vivo, since mitochondrial ROS generation may also
trigger secondary increased NADPH oxidase expression/activity
and interrelated ROS production.43 In fact, we implicated for the
first time a possible role of NADPH oxidase-derived ROS in the car-
diotoxicity of DOX in vivo,16 even though the expression of various
NADPH oxidase isoforms was not altered in the acute model of car-
diomyopathy used,12 which probably require more time to develop.
Indeed, in the cDOX-induced cardiomyopathy model, we found
increased mRNA expressions of various NADPH oxidase isoforms
(gp91phox, NOX4, and p67phox; Figure 6C) suggesting a more pro-
nounced role of NADPH oxidase-derived ROS in the development
of cDOX-induced cardiotoxicity. Remarkably, these changes were
also attenuated in CB1 knockouts, consistently with decreased oxi-
dative stress.
We propose that DOX initially rapidly increases mitochondrial
reactive oxygen species generation in cardiomyocytes and/or endo-
thelial cells by redox cycling triggering a cascade of events impairing
mitochondrial function and resulting in more sustained oxidative/
nitrosative stress, which persists even after the DOX is completely
metabolized. In turn, the oxidative/nitrosative stress triggers the
activation of MAPKs, and inactivates important enzymes/proteins
involved in normal cardiac homeostasis and contractile function,
eventually culminating into cell death of cardiomyocytes/endothelial
cells and cardiac dysfunction. The oxidative/nitrosative stress may
also trigger secondary expression of various NADPH oxidases
further amplifying the vicious circle of ROS generation.
Oxidative/nitrosative stress also triggers increased endocannabi-
noid production44,45 and/or inactivation of the endocannabinoid
metabolizing enzyme FAAH (the main regulator of the tissue endo-
cannabinoid levels because of the rapid metabolism) as observed in
our recent study. Consequently, the endocannabinoids by activat-
ing CB1 receptors in cardiomyocytes can trigger increased reactive
oxygen species production, MAPK activation, and cell death. Con-
sistent with our results in cardiomyocytes, a recent study has ele-
gantly demonstrated a pivotal role of CB1 receptors in reactive
oxygen species generation by macrophages.46
Collectively, these data suggest that CB1 activation in cardio-
myocytes amplifies the reactive oxygen/nitrogen species-MAPK
activation-cell death pathway in pathological conditions when the
endocannabinoid synthetic or metabolic pathways are dysregulated
by excessive inflammation and/or oxidative/nitrosative stress (e.g.
in various forms of shock, cardiomyopathy/heart failure, and
atherosclerosis), which contributes to the pathophysiology of
these cardiovascular diseases (as also demonstrated presently in
case of DOX-induced cardiomyopathy models). In these diseases,
CB1 receptor antagonists with limited CNS penetration may offer a
cardioprotective strategy. Our results also unravel the fundamen-
tals of the CB1 signalling in human cardiomyocytes facilitating the
better understanding of the beneficial effects of CB1 antagonists
observed in preclinical cardiovascular disease models, as well as
in clinical trials. The resistance of CB1 knockout mice against myo-
cardial fibrosis in the chronic cardyomyopathy model may also
have very important clinical implications and should be explored
in the future studies. Furthermore these CB1-mediated signalling
mechanisms may also be involved in cardiotoxicity of cannabis
occasionally reported in some users.
Supplementary material
Supplementary material is available at Cardiovascular Research
online.
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